Mastodon

Diafuril (Capsules, Suspension) Instructions for Use

ATC Code

A07AX03 (Nifuroxazide)

Active Substance

Nifuroxazide (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Intestinal antiseptic. Antidiarrheal agent

Pharmacotherapeutic Group

Antidiarrheals, intestinal anti-inflammatory/antimicrobial agents; intestinal antimicrobial agents; other intestinal antimicrobial agents

Pharmacological Action

An antimicrobial agent, a nitrofuran derivative. It blocks the activity of dehydrogenases and inhibits the respiratory chains, the tricarboxylic acid cycle, and a number of other biochemical processes in the microbial cell. It destroys the microbial cell membrane and reduces toxin production by microorganisms.

It is highly active against Campylobacter jejuni, Escherichia coli, Salmonella spp, Shigella spp; Clostridium perfringens, Vibrio cholerae, pathogenic Vibrions and Vibrio parahaemolytique, Staphylococcus spp. Weakly sensitive to nifuroxazide: Citrobacter spp, Enterobacter cloacae and Proteus indologenes. Resistant to nifuroxazide: Klebsiella spp, Proteus mirabilis, Providencia spp., Pseudomonas spp.

It does not disturb the balance of the intestinal microflora. In acute bacterial diarrhea, it restores intestinal eubiosis. When infected with enterotropic viruses, it prevents the development of bacterial superinfection.

Pharmacokinetics

After oral administration, Nifuroxazide is practically not absorbed from the gastrointestinal tract and acts in the intestinal lumen. It is excreted through the intestine: 20% unchanged, the rest is chemically altered.

Indications

Acute bacterial diarrhea occurring without worsening of the general condition, fever, or intoxication.

ICD codes

ICD-10 code Indication
A09 Other and unspecified gastroenteritis and colitis of infectious origin
ICD-11 code Indication
1A40.Z Infectious gastroenteritis or colitis, unspecified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Administer orally. Select the dosage form and regimen based on the patient’s age.

For adults and children over 6 years: administer two 200 mg capsules four times daily. Maintain regular 6-hour intervals between doses.

For children from 2 to 6 years: use the oral suspension. Administer 5 ml (220 mg) four times daily. Use the measuring spoon provided.

For children from 1 to 2 months: use the oral suspension. Administer 2.5 ml (110 mg) two or three times daily. Adhere to the prescribed frequency.

The standard treatment duration is 5 to 7 days. Do not exceed a 7-day course of therapy.

If symptoms persist after 3 days of treatment, re-evaluate the patient and diagnosis.

Initiate oral rehydration concurrently to prevent and correct fluid and electrolyte losses.

Adverse Reactions

Allergic reactions skin rash, urticaria, angioedema, anaphylactic shock.

Contraindications

Hypersensitivity to nitrofuran derivatives; pregnancy; childhood – depending on the dosage form.

With caution liver disease, alcoholism, craniocerebral trauma, brain diseases; breastfeeding period; childhood.

Use in Pregnancy and Lactation

The use of nifuroxazide during pregnancy is not recommended. During lactation (breastfeeding), it should be used with caution, in a short course.

Pediatric Use

In children, use with caution, according to indications, in doses and dosage forms recommended for the respective age. It is necessary to strictly follow the instructions in the nifuroxazide drug leaflets regarding contraindications for the use of specific nifuroxazide dosage forms in children of different ages.

Special Precautions

When treating diarrhea, rehydration therapy must be carried out simultaneously with nifuroxazide therapy.

In case of bacterial diarrhea occurring with a worsening of the general condition, fever, symptoms of intoxication or infection, you should consult a doctor to decide on the use of systemic antibacterial drugs. If symptoms of hypersensitivity (shortness of breath, rash, itching) appear, nifuroxazide should be discontinued.

Consumption of alcohol during nifuroxazide therapy is prohibited.

Drug Interactions

Concomitant use with drugs that cause disulfiram-like reactions, and with drugs that depress the function of the central nervous system, is not recommended.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Alkaloid AD Skopje (Republic of North Macedonia)

Dosage Form

Bottle OTC Icon Diafuril Suspension for oral administration 200 mg/5 ml: fl. 90 ml with measuring cup

Dosage Form, Packaging, and Composition

Oral suspension yellow, homogeneous, with a characteristic banana smell.

5 ml
Nifuroxazide 200 mg

Excipients : liquid sorbitol, glycerol, sodium citrate dihydrate, carbomer 940, masking flavor, sodium benzoate, sodium saccharin, banana flavor, simethicone emulsion 30%, disodium edetate, polysorbate 80, purified water.

90 ml – dark glass bottles (1) with a measuring cup – cardboard packs.

Marketing Authorization Holder

Alkaloid AD Skopje (Republic of North Macedonia)

Dosage Forms

Bottle OTC Icon Diafuril Capsules 100 mg: 30 pcs.
Capsules 200 mg: 20 pcs.

Dosage Form, Packaging, and Composition

Capsules hard gelatin, size No. 2, with a yellow body and cap; capsule contents – bright yellow powder.

1 caps.
Nifuroxazide 100 mg

Excipients : microcrystalline cellulose (Avicel PH101), corn starch, povidone K25, colloidal silicon dioxide, sodium lauryl sulfate, magnesium stearate.

Composition of the hard gelatin capsule gelatin, titanium dioxide (E171), yellow iron oxide (E172).

10 pcs. – blisters (3) – cardboard packs.


Capsules hard gelatin, size No. 1, with a yellow body and cap; capsule contents – bright yellow powder.

1 caps.
Nifuroxazide 200 mg

Excipients : microcrystalline cellulose (Avicel PH101), corn starch, povidone K25, colloidal silicon dioxide, sodium lauryl sulfate, magnesium stearate.

Composition of the hard gelatin capsule gelatin, titanium dioxide (E171), yellow iron oxide (E172).

10 pcs. – blisters (2) – cardboard packs.

TABLE OF CONTENTS